Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Huub Schellekens"'
Autor:
Guilherme S. Ferreira, Francis M. Dijkstra, Désirée H. Veening-Griffioen, Wouter P. C. Boon, Huub Schellekens, Ellen H. M. Moors, Peter J. K. van Meer, Frederik E. Stuurman, Joop M. A. van Gerven
Publikováno v:
Translational Psychiatry, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract The primary purpose of this study was to assess the translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system (CNS) active drugs. As a part of this, IBs were reviewed on re
Externí odkaz:
https://doaj.org/article/969744b409794e0e8e65ec07d7ce391d
Autor:
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Ellen H M Moors, Christine C Gispen-de Wied, Huub Schellekens, Peter J K van Meer
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218014 (2019)
IntroductionPoor translation of efficacy data derived from animal models can lead to clinical trials unlikely to benefit patients-or even put them at risk-and is a potential contributor to costly and unnecessary attrition in drug development.Objectiv
Externí odkaz:
https://doaj.org/article/0f14ca084e9b487cb8a1f7e01b4a38f6
Autor:
Guilherme S Ferreira, Désirée H Veening-Griffioen, Wouter P C Boon, Ellen H M Moors, Christine C Gispen-de Wied, Huub Schellekens, Peter J K van Meer
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0220325 (2019)
[This corrects the article DOI: 10.1371/journal.pone.0218014.].
Externí odkaz:
https://doaj.org/article/4a9a1b7212f24fd09f77e8357dbb8bd4
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Many biopharmaceuticals exhibit mixed heterogeneity in their post-translational modifications (PTMs) that are essential for their function. Here the authors use a combination of mass spectrometry techniques to analyse human erythropoietin (EPO) and p
Externí odkaz:
https://doaj.org/article/b02ee70614ff4f99a5c217410f8e376c
Autor:
Francesco Scaglione, Paola Minghetti, Francesco Ambrosio, Beat Ernst, Vicenzo Ficarra, Marco Gobbi, Kurt Naber, Huub Schellekens
Background: the nature of alpha-D-mannose - natural aldohexose sugar, C-2 glucose epimer, whose intended use is for preventing urinary tract infections - in the interaction with E. coli is addressed in order to drive the issue of its regulatory class
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3456959904000bb4bb2f2fa9c769e081
https://doi.org/10.20944/preprints202301.0234.v1
https://doi.org/10.20944/preprints202301.0234.v1
Autor:
Erik Doevendans, Huub Schellekens
Publikováno v:
Antibodies, Vol 8, Iss 1, p 21 (2019)
The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Milstein (1975) counts as one of the major medical breakthroughs, opening up endless possibilities for research, diagnosis and for treatment of a whole v
Externí odkaz:
https://doaj.org/article/577c0bbeafcd46c5bf008ecca25bb698
Autor:
Huub Schellekens, Erik Doevendans
Publikováno v:
Journal of Pharmaceutical Sciences. 109:2962-2968
The current pharmaceutical system is not sustainable; new drugs have limited impact on public health, they are (too) expensive and innovation has stalled because of overregulation of the industry. We suggest reviving compounding by pharmacists as the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b33495fb61f8f37244d115a8674f93d8
https://doi.org/10.1016/j.xphs.2020.07.009
https://doi.org/10.1016/j.xphs.2020.07.009
Autor:
Huub Schellekens, Marcel den Hartog, Mohammed H Aldosari, Martijn J W Evers, Hubertina Ganizada, Enrico Mastrobattista
Publikováno v:
Current Pharmaceutical Biotechnology. 21:467-479
Objective: The high cost of orphan drugs limits their access by many patients, especially in low- and middle-income countries. Many orphan drugs are off-patent without alternative generic or biosimilar versions available. Production of these drugs at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81bcc5f1fdd81d4b1ca6bf2fa07ebc0f
https://doi.org/10.2174/1389201021666200217113049
https://doi.org/10.2174/1389201021666200217113049
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e85281 (2014)
Protein aggregates are a major risk factor for immunogenicity. Until now most studies on aggregate-driven immunogenicity have focused on linking physicochemical features of the aggregates to the formation of anti-drug antibodies. Lacking is however,
Externí odkaz:
https://doaj.org/article/8f13435971424eb6882d96c10e83a92b